Quick Answer
Jazz Pharmaceuticals plc reported Cash and Equivalents of $1.39 billion for fiscal year 2025.
Jazz Pharmaceuticals plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.39B | -42.3% |
| 2024 | $2.41B | +60.2% |
| 2023 | $1.51B | +70.9% |
| 2022 | $881.48M | +49.0% |
| 2021 | $591.45M | -44.1% |
| 2020 | $1.06B | +66.0% |
| 2019 | $637.34M | +105.8% |
| 2018 | $309.62M | -19.8% |
| 2017 | $386.04M | +5.5% |
| 2016 | $365.96M | -63.0% |
| 2015 | $988.78M | +44.6% |
| 2014 | $684.04M | +7.5% |
| 2013 | $636.50M | +64.4% |
| 2012 | $387.20M | +371.8% |
| 2011 | $82.08M | +83.2% |
| 2010 | $44.79M | +187.2% |
| 2009 | $15.60M | -37.4% |
| 2008 | $24.90M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.33B | -40.2% | +11.4% |
| June 30, 2025 | $1.19B | -12.2% | -36.1% |
| March 31, 2025 | $1.86B | +29.0% | -22.8% |
| December 31, 2024 | $2.41B | +60.2% | +8.8% |
| September 30, 2024 | $2.22B | +66.1% | +63.6% |
| June 30, 2024 | $1.36B | +5.7% | -6.1% |
| March 31, 2024 | $1.44B | +23.6% | -4.2% |
| December 31, 2023 | $1.51B | +70.9% | +12.8% |
- Jazz Pharmaceuticals plc showed a decrease of -42.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Jazz Pharmaceuticals plc’s cash and equivalents has grown by 5489.3% (from $24.90 million to $1.39 billion).
- The most recent figure is from Jazz Pharmaceuticals plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: